… Since the beginning of the 1980s, more than 1,700 patients with ASTS have been included
in randomized phase III trials comparing the activity of single-agent doxorubicin with various …

… with an institutional diagnosis of MB were stratified by local invasion and metastatic stage
(Chang T/M) and randomized to therapy. Median time at risk from study entry was 7.0 years. …

… This was an open-label randomized Phase III study of 207 patients with either unresectable
or metastatic non-small cell lung cancer (NSCLC) who were treated with docetaxel plus best …

… We present the long-term results of a randomized trial of induction chemotherapy in …
The long-term follow-up of a randomized study conducted in Italy showed that induction …

… Study design In a randomized phase III trial, 610 patients with inoperable stage II or III
non–small cell lung cancer were randomly assigned to two different concurrent regimens (…

… • In a randomized Phase II study, atezolizumab + bevacizumab resulted in encouraging …
• A randomized Phase III study of atezolizumab + bevacizumab vs sunitinib was conducted …

… The difference in results obtained in the phase II and III parts, … population prognosis in the
phase III study, notably with … in this study is consistent with that reported for other phase III …

… phase III trial. A similar report of activity with an acceptable level of toxicity for the combination
of topotecan plus cisplatin 15 led to the development of GOG 179, a randomized phase III …

… In this study, 240 and 239 patients were randomized to CCRT and I-CCRT arm, respectively.
The most prominent toxicities of induction were leukopenia (grade 3 and 4: 47% and 12%) …

Purpose This phase III study investigated whether continuation maintenance with
gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with …